Year: 2022

In this episode, we delve into the crucial role of translating data insights into actionable strategies, emphasizing the significance of reaching the right audience and driving meaningful outcomes.

In this episode, Thomas Debray and I dive back into the intriguing world of personalized medicine. We explore the advancements, and hurdles in customizing patient care.

In this discussion, Liz presents some of the most distinct reasons as to why a statistician may want to embrace other options of growth in the healthcare industry as an advocate for distinct purposes.

n our discussion, Gary and I exchange thoughts, and experiences and learned lessons through the years and how they can be applied in actual situations that statisticians face at work.

In this episode, Jenny Devenport and I talk about these publications as a critical part of the scientific process We also cover how creating these helps establish credibility with various stakeholders.

A secondary paper is a paper you do once you are done with your primary paper. I’ve been working on this for a long time and always have fun doing it.

In this episode, I am talking about the reasons why people stay in their comfort zones and always choose the “safe side”. And why choosing this hinders you from your personal and career growth.

I am really passionate about leadership and Claude Petit is also passionate about building leaders and being an effective leader. Together, we will share with you how to become a statistical leader, how to build an organization of leaders, her very interesting leadership journey, and what it actually means to be a Statistician.

My experience of working with pharmacometricians was very limited because I spent most of my time working more on the later phases. The contact with people in pharmacology in the later phases of the industry is not that big. That’s why I found this episode really helpful. If you don’t have a clue what happens in pharmacology, then stay tuned for this episode.

You got regulatory approval for a new indication earlier than expected. While the regulatory team celebrates the achievement you worry that you need to have your NMA ready 3 months earlier. Will you be able to deliver?

We discuss these and many more problems of NMAs.